The very-high-efficacy 5-HT1A receptor agonist, F 13640, preempts the development of allodynia-like behaviors in rats with spinal cord injury

Wei Ping Wu, Jing Xia Hao, Xiao Jun Xu, Zsuzsanna Wiesenfeld-Hallin, Wouter Koek, Francis C. Colpaert

Research output: Contribution to journalArticlepeer-review

30 Scopus citations

Abstract

Central neuropathic pain after spinal cord injury (SCI) presents a challenging clinical problem with limited treatment options. [(3-chloro-4-fluoro-phenyl)-[4-fluoro-4-{[(5-methyl-pyridin-2-ylmethyl)-amino] -methyl}piperidin-1-yl]]-methadone (F 13640) is a recently discovered very-high-efficacy, selective 5-HT1A receptor agonist that produces a remarkably powerful, central analgesia through unprecedented neuroadaptive mechanisms. In a rat model of spinal cord injury pain, we previously found that chronic infusion of F 13640 alleviated pain-like behaviors. Here, we report that infusion of 0.63 mg/day of F 13640 for 8 weeks starting 24 h before the induction of injury significantly attenuates the development of chronic allodynia-like behavior in rats sustaining a photochemically-induced, ischaemic injury of the dorsal laminae of the L3-L5 segments of the spinal cord. Importantly, the preemptive effect of F 13640 persisted for 2 months after treatment was discontinued. The data warrant the study of the possible effects of the early administration of F 13640 in patients sustaining spinal cord injury.

Original languageEnglish (US)
Pages (from-to)131-137
Number of pages7
JournalEuropean Journal of Pharmacology
Volume478
Issue number2-3
DOIs
StatePublished - Oct 8 2003
Externally publishedYes

Keywords

  • 5-HT receptor
  • Analgesia
  • Neuropathic pain
  • Serotonin

ASJC Scopus subject areas

  • Pharmacology

Fingerprint

Dive into the research topics of 'The very-high-efficacy 5-HT<sub>1A</sub> receptor agonist, F 13640, preempts the development of allodynia-like behaviors in rats with spinal cord injury'. Together they form a unique fingerprint.

Cite this